Publicerat: 2020-10-26 08:30:06

MarketWire om RhoVac AB: Article on RhoVac's Phase I/II study to be published in November

As previously disclosed, the article elaborating on the results of RhoVac's Phase I/II study in prostate cancer including the 12-month follow-up period, has been accepted for publication in the Journal for ImmunoTherapy of Cancer (JITC). The publication now indicates that the release of the article will take place in November, a few weeks later than previously suggested. The article will feature an elaboration on the mode of action of RV001, but also a discussion on the PSA data findings indicating possibilities of delaying disease progression, for which RhoVac's currently ongoing phase IIb study is aimed at providing substantial evidence.RhoVac's CEO, Anders Månsson, comments: "Despite the minor delay, I am very happy about the confirmation on the publication of this article. We have waited for this publication a long time, and now and I am excited to address its findings with our potential partners."This disclosure contains information that RhoVac is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 26-10-2020 08:30 CET.RhoVac

Läs mer om RhoVac AB